About 5-hydroxytryptamine receptor 1B
5-hydroxytryptamine receptor 1B (HTR1B) is a protein
from Homo sapiens identified by UniProt accession
P28222, 390 residues long.
MolForge cross-references it against 0 known binders and
182 disease associations.
Target properties
| Protein name | 5-hydroxytryptamine receptor 1B |
| UniProt accession | P28222 |
| Gene | HTR1B |
| Organism | Homo sapiens |
| Length | 390 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Approved drugs hitting this target (16)
DrugCentral-linked approved drugs that act on this protein.
Disease associations (182)
Diseases linked to this target (Open Targets).
- migraine disorder · score 0.61
- schizophrenia · score 0.61
- Headache · score 0.53
- cardiovascular disease · score 0.53
- pain · score 0.51
- mental or behavioural disorder · score 0.50
- schizoaffective disorder · score 0.50
- migraine with aura · score 0.50
- migraine without aura · score 0.50
- post operative nausea and vomiting · score 0.47
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-P28222-F1 | alphafold | PREDICTED | 79.18 | — |
Amino-acid sequence (390 residues)
MEEPGAQCAP PPPAGSETWV PQANLSSAPS QNCSAKDYIY QDSISLPWKV LLVMLLALIT LATTLSNAFV IATVYRTRKL HTPANYLIAS LAVTDLLVSI LVMPISTMYT VTGRWTLGQV VCDFWLSSDI TCCTASILHL CVIALDRYWA ITDAVEYSAK RTPKRAAVMI ALVWVFSISI SLPPFFWRQA KAEEEVSECV VNTDHILYTV YSTVGAFYFP TLLLIALYGR IYVEARSRIL KQTPNRTGKR LTRAQLITDS PGSTSSVTSI NSRVPDVPSE SGSPVYVNQV KVRVSDALLE KKKLMAARER KATKTLGIIL GAFIVCWLPF FIISLVMPIC KDACWFHLAI FDFFTWLGYL NSLINPIIYT MSNEDFKQAF HKLIRFKCTS
Explore 5-hydroxytryptamine receptor 1B with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets